Zhejiang Jingxin Pharmaceutical Valuation

Q: What is the Fair Price of 002020 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002020 (CN¥12.95) is trading below our estimate of [[fair value]] (CN¥29.07)

Is 002020 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002020 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002020 (CN¥12.95) is trading below our estimate of fair value (CN¥29.07)

Significantly Below Fair Value: 002020 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002020?

Key metric: As 002020 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002020. This is calculated by dividing 002020's market cap by their current earnings.
What is 002020's PE Ratio?
PE Ratio	15.5x
Earnings	CN¥721.29m
Market Cap	CN¥11.15b

002020 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	11.7x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does 002020's PE Ratio compare to its peers?

The above table shows the PE ratio for 002020 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.7x
605507 Guobang Pharma	17x	22.6%	CN¥12.0b
002287 Tibet Cheezheng Tibetan Medicine	20.3x	n/a	CN¥12.0b
002737 Sunflower Pharmaceutical GroupLtd	13.9x	n/a	CN¥11.9b
600664 Harbin Pharmaceutical Group	15.5x	n/a	CN¥9.5b
002020 Zhejiang Jingxin Pharmaceutical	15.5x	14.4%	CN¥11.2b

Price-To-Earnings vs Peers: 002020 is good value based on its Price-To-Earnings Ratio (15.5x) compared to the peer average (16.7x).

Price to Earnings Ratio vs Industry

How does 002020's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002020 is good value based on its Price-To-Earnings Ratio (15.5x) compared to the CN Pharmaceuticals industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 002020's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002020 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.5x
Fair PE Ratio	24.1x

Price-To-Earnings vs Fair Ratio: 002020 is good value based on its Price-To-Earnings Ratio (15.5x) compared to the estimated Fair Price-To-Earnings Ratio (24.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.66

2.6%

14.2%

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

-0.4%

15.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.2b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

-5.1%

14.5%